Andrea Armirotti

The paper designs a high-affinity CLDN5 peptide binder, ST9, that induces reversible, size-controlled BBB openings without altering CLDN5 expression or proteomic profile.

The paper identifies human ASPDH as a 2-aminomuconate reductase in tryptophan catabolism, revealing a new branch of the kynurenine pathway and an unknown amino acid.

This study identifies NAPEs as regulators of LRRK2 and lysosomal function in Parkinson's disease, showing that boosting NAPEs reduces LRRK2 activity and clears alpha-synuclein aggregates.

This study identifies synergistic microRNAs that suppress glioblastoma progression by targeting key pathways and genes associated with tumor growth and poor prognosis.

This study shows that CaMKIV phosphorylation of REST at Ser-322 reduces its repressor activity and promotes its degradation.

This study identifies CDC42 inhibitors that reduce vessel branching in both normal skin and tumors, offering potential for treating skin cancer and angiogenesis-related diseases.

This study evaluates miRNA-based therapy for medulloblastoma using a xenotransplant model, showing reduced tumor growth and invasiveness through miRNA restoration.

The paper designs and tests peptides that bind claudin-5 to increase blood-brain barrier permeability, identifying a peptide that effectively enhances permeability in vitro.

This study examines how ALS-associated FUS mutations alter the RNA and protein composition of Stress Granules in neural cells, revealing molecular changes linked to neurodegeneration.

The paper analyzes myelin lipid composition and structure in CMT1A rats to show delayed maturation of myelin and axon development.

This paper investigates brain network and behavioral changes in a mouse model of CTD and shows that perinatal gene therapy can partially reverse some symptoms but not all.

This study identifies SINEUP RNAs with Internal Ribosomal Entry Site (IRES) sequences as effector domains, enhancing translation of target mRNAs through both linear and circular transcripts.

This paper designs a CDC42 effector interaction inhibitor (ARN22089) that shows anti-cancer activity by blocking tumor invasion and angiogenesis.

This study uses chemogenetic-fMRI to identify brain regions activated by serotonergic stimulation, showing region-specific effects rather than global activity changes.